Geode Capital Management
CTOR

Geode Capital Management’s Citius Oncology CTOR Stock Holding History

Geode Capital Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Sell
245,407
-19,326
-7% -$15.4K ﹤0.01% 3984
2026
Q1 		$164K Buy
264,733
+44,686
+20% +$44.9K ﹤0.01% 3987
2025
Q4 		$220K Buy
220,047
+52,875
+32% +$75.8K ﹤0.01% 3868
2025
Q3 		$339K Buy
167,172
+109,875
+192% +$238K ﹤0.01% 3749
2025
Q2 		$249K Buy
57,297
+36,758
+179% +$42.9K ﹤0.01% 3800
2025
Q1 		$19.1K Buy
20,539
+7,888
+62% +$8.45K ﹤0.01% 4356
2024
Q4 		$14.5K Buy
+12,651
New +$14.2K ﹤0.01% 4408

Other funds holding CTOR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management's CTOR Position: Q2 2026 in Review

Geode Capital Management reduced its Citius Oncology (CTOR) stake by 7.3% in Q2 2026, selling an estimated $15.4K and leaving 245,407 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #3984.

Geode Capital Management first reported a position in CTOR in Q4 2024 and has held it in 7 quarters since. The position peaked at $339K in Q3 2025. 19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

  • Geode Capital Management held 245,407 shares of Citius Oncology worth $160K as of Q2 2026.
  • Geode Capital Management sold 19,326 Citius Oncology shares in Q2 2026, an estimated $15.4K.
  • Citius Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3984 holding.
  • Geode Capital Management first reported a position in Citius Oncology in Q4 2024 and has held it in 7 quarters since.
  • Geode Capital Management's Citius Oncology position peaked at $339K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.